Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$9.34 – $17.85
61% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.31T | $1.30T | $1.25T | $1.30T | $1.52T | $1.60T | $1.91T | $2.15T |
| Cost of revenue | $292.05B | $276.74B | $246.06B | $253.01B | $288.35B | $292.49B | $349.21B | $547.83B |
| Gross profit | $1.01T | $1.02T | $1.00T | $1.04T | $1.23T | $1.31T | $1.56T | $1.60T |
| Gross margin | 77.6% | 78.7% | 80.3% | 80.5% | 81.0% | 81.8% | 81.7% | 74.6% |
| R&D | $208.68B | $224.23B | $224.49B | $246.01B | $276.13B | $294.20B | $327.65B | $316.81B |
| Operating income | $243.91B | $243.99B | $136.05B | $220.02B | $133.03B | $25.52B | $41.04B | $422.34B |
| EBITDA | $313.73B | $314.75B | $323.58B | $297.83B | $337.39B | $194.81B | $248.05B | $618.16B |
| Net income | $222.26B | $195.41B | $120.59B | $124.09B | $98.71B | $17.05B | $50.75B | $293.37B |
| Net margin | 17.0% | 15.0% | 9.7% | 9.6% | 6.5% | 1.1% | 2.7% | 13.6% |
| EPS (diluted) | 114.94 | 104.08 | 64.90 | 67.05 | 54.09 | 9.47 | 28.24 | 162.98 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $2.25T | $182.62 | $174.47–$196.33 | 2 |
| 2028 | $2.09T | $183.25 | $175.07–$197.01 | 3 |
| 2029 | $1.85T | $139.23 | $133.02–$149.69 | 4 |
| 2030 | $1.71T | $123.83 | $118.31–$133.13 | 2 |
Forward consensus · source: Financial Modeling Prep
ASTELLAS PHARMA INC
No one on the platform currently holds ALPMF.
No tracked institution reports a position in ALPMF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2027-03-31 | $40.0000 | |
| 2026-09-30 | $40.0000 | |
| 2026-03-31 | $39.0000 | 2026-06-03 |
| 2025-09-30 | $39.0000 | 2025-12-01 |
| 2025-03-31 | $37.0000 | 2025-06-03 |
| 2024-09-30 | $37.0000 | 2024-12-02 |
| 2024-03-28 | $35.0000 | 2024-06-03 |
| 2023-09-29 | $35.0000 | 2023-12-01 |
No one on the platform has traded ALPMF yet.
| +0.00% |
| $12.1B |
| — |
| GIKLYGrifols, S.A. | $5.10 | +0.00% | $13.4B | — |
| GNMSFGenmab A/S | $275.00 | +10.00% | $16.9B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.5× earnings vs its 0.3× historical median P/E.
Fair value ≈ $7.13 · price $14.50 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.